Target intelligence / Profile preview

cAMP-dependent protein kinase catalytic subunit alpha (PRKACA)

Target
PRKACA
Molecular classification
Enzyme, Serine/threonine-protein kinase, AGC kinase family
01

Overview

cAMP-dependent protein kinase catalytic subunit alpha (PRKACA), also known as the catalytic subunit alpha of protein kinase A (PKA), is a key serine/threonine kinase that plays a central role in the cyclic AMP (cAMP) signaling pathway. Under physiological conditions, PRKACA exists as an inactive tetrameric holoenzyme complexed with regulatory subunits; upon cAMP binding, the catalytic subunits are released to phosphorylate a wide array of downstream substrates involved in glucose metabolism, cell proliferation, and cardiovascular function. Somatic gain-of-function mutations in PRKACA (such as L206R) lead to constitutive, cAMP-independent activation, driving cortisol-producing adrenocortical adenomas and Cushing's syndrome. Furthermore, a recurrent chromosomal deletion on chromosome 19 fuses PRKACA with DNAJB1, producing the oncogenic DNAJB1-PRKACA fusion kinase that drives fibrolamellar hepatocellular carcinoma (FL-HCC). Therapeutic strategies targeting PRKACA include highly selective, ATP-competitive small-molecule inhibitors (such as BLU2864, BLU0588, and DS89002333) and neoantigen-targeting peptide vaccines designed to elicit T-cell responses against the DNAJB1-PRKACA fusion protein. However, because PKA is ubiquitously expressed and regulates vital cellular processes, developing PRKACA-targeted therapies presents significant safety challenges, particularly regarding potential cardiovascular and metabolic toxicities.

Other names
Protein kinase A catalytic subunit alphaPKA C-alphaPKACAProtein kinase cAMP-activated catalytic subunit alpha
02

Mechanism of action

ATP-competitive kinase inhibition of the catalytic subunit of protein kinase A, or active immunotherapy targeting the DNAJB1-PRKACA fusion neoantigen

03

Biological functions

Signal transductionGlucose metabolismLipid metabolismCell proliferationCell cycle regulationApoptosis regulationPlatelet activationSmoothened signaling pathway inhibition
04

Disease associations

CancerCardiovascular diseasePolycystic kidney diseaseEndocrine disorders
05

Safety considerations

Narrow therapeutic window due to ubiquitous expressionCardiovascular toxicities (e.g., arrhythmias, altered cardiac contractility)Metabolic disturbances (disruption of glucose and lipid metabolism)Off-target kinase inhibition
06

Interacting drugs

BLU2864

9 more in the full profile.

07

Biomarkers

DNAJB1-PRKACA fusion genePRKACA somatic mutations (e.g., L206R, L205R)Phospho-VASP (pVASP) levelsPhospho-CREB (pCREB) levels

Beyond the preview

Go deeper on cAMP-dependent protein kinase catalytic subunit alpha (PRKACA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cAMP-dependent protein kinase catalytic subunit alpha (PRKACA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call